HighMark Wealth Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-580
Closed -$1.57K 633
2023
Q1
$1.57K Hold
580
﹤0.01% 520
2022
Q4
$2.31K Sell
580
-1
-0.2% -$6 ﹤0.01% 421
2022
Q3
$4K Hold
581
﹤0.01% 382
2022
Q2
$7K Hold
581
0.01% 312
2022
Q1
$10K Hold
581
0.01% 275
2021
Q4
$38K Hold
581
0.02% 137
2021
Q3
$40K Hold
581
0.03% 131
2021
Q2
$40K Hold
581
0.03% 133
2021
Q1
$38K Buy
581
+25
+4% +$1.9K 0.03% 121
2020
Q4
$32K Buy
556
+112
+25% +$6.52K 0.03% 130
2020
Q3
$26K Buy
444
+166
+60% +$14.8K 0.02% 146
2020
Q2
$36K Buy
278
+56
+25% +$4.95K 0.04% 92
2020
Q1
$13K Sell
222
-845
-79% -$82.7K 0.02% 141
2019
Q4
$134K Buy
+1,067
New +$145K 0.14% 47

HighMark Wealth Management's HTGM Position: Q2 2023 in Review

HighMark Wealth Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2023, closing a stake of 580 shares — an estimated $1.57K sold.

HighMark Wealth Management first reported a position in HTGM in Q4 2019 and held it in 14 quarters. The position peaked at $134K in Q4 2019. 0 funds tracked by Wall St. Rank hold HTGM as of Q2 2023.

  • HighMark Wealth Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • HighMark Wealth Management sold 580 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2023, an estimated $1.57K.
  • HighMark Wealth Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q4 2019 and held it in 14 quarters.
  • HighMark Wealth Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $134K in Q4 2019.
  • 0 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2023.

Based on HighMark Wealth Management's 13F filing for Q2 2023, filed 26 Jul 2023.